Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program

Journal of Urban Health

Volumn 78, Issue 3, 2001, Pages 550-567

  Mullol, J ^a   Roca Ferrer, J ^a   Xaubet, A ^a   Traserra, J ^a   Picado, C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRIDOXINE;

ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PATIENT COMPLIANCE; PATIENT REFERRAL; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REIMBURSEMENT; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULOSIS;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; ISONIAZID; MALE; MASS SCREENING; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; NEW YORK CITY; SUBSTANCE ABUSE, INTRAVENOUS; TUBERCULOSIS;

EID: 0034856522     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/78.3.550     Document Type: Article

References (64)

1. Drug dependence, a possible new risk factor for tuberculosis disease
2. Tuberculosis in drug users
3. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection
4. Controlled chemoprophylaxis trials in tuberculosis. A general review
5. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial
6. A controlled trial of community wide isoniazid prophylaxis in Alaska
7. Preventive tuberculosis chemotherapy with isoniazid among persons infected with HIV-1
8. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
9. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus
10. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection
11. Review of published cost-effectiveness studies on tuberculosis treatment programmes
12. Health-care expenditures for tuberculosis in the US
13. Preventive therapy for tuberculosis in HIV-infected persons: Analysis of policy options based on tuberculin status and CD4+ cell count
14. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: An operational assessment at a voluntary counseling and testing centre
15. Effects of an incentive program on return rates for PPD test reading in patients with HIV infection
16. Tuberculosis screening and compliance with return for skin test reading among active drug users
17. Preventive therapy for tuberculosis
18. Targeted tuberculin testing treatment of latent tuberculosis infection
19. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program
20. Directly observed therapy for tuberculosis: History of an idea
21. Community-wide implementation of targeted testing for and treatment of latent tuberculosis infection
22. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis
23. Primary care for patients with human immunodeficiency virus infection (HIV) in a methadone maintenance program
24. Tuberculosis prevention in drug treatment centers and correctional facilities - Selected US sites, 1990-1991
25. Cost-effectiveness of directly observed chemoprophylaxis among drug users at high risk for tuberculosis
26. Tuberculosis screening at a syringe exchange
27. Organizational issues in conducting tuberculosis screening at a syringe exchange
28. Tuberculosis directly observed preventive therapy for active drug users
29. Diagnostic standards and classification of tuberculosis in adults and children
30. Preventive therapy with isoniazid: Cost-effectiveness of different durations of therapy
31. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
32. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine
33. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine
34. Tuberculosis prevention: Cost-effectiveness analysis of isoniazid chemoprophylaxis
35. Incidence of tuberculosis in the US among HIV-infected persons
36. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection
37. Risk factors for human immunodeficiency virus infection in intravenous drug users
38. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy
39. Risk for developing tuberculosis among anergic patients infected with HIV
40. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis
41. The economic impact of tuberculosis in hospitals in New York City: A preliminary analysis
42. Reliability of anergy skin testing in person with HIV infection
43. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection
44. Criteria for assessing cutaneous anergy in women with or at risk for HIV infection
45. Anergy skin testing preventive therapy for HIV-infected persons Revised recommendations
46. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis
47. Resurgent tuberculosis in New York City: Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs
48. Two stage tuberculin skin testing in an HIV-infected population: A preliminary report
49. Prophylaxis and treatment of HIV-related tuberculosis
50. Utilization of on site primary care services in a methadone maintenance program
51. Syringe exchange in the US, 1996: A national profile
52. Help-seeking and referrals in a needle exchange: A comprehensive service to injecting drug users
53. Three years of needle exchange in New Haven: What have we learned?
54. Provision of influenza and pneumococcal vaccine to injection drug users at a syringe exchange
55. Adherence to tuberculosis preventive therapy among HIV-infected persons in Chaing Rai, Thailand
56. Risk factors for tuberculosis in HIV infected persons: A prospective cohort study
57. A prospective study of the risk of tuberculosis among HIV-infected patients
58. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adult?
59. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection
60. Rifampin-induced methadone withdrawal
61. Implications of directly observed therapy in tuberculosis control measures among IDUs
62. Hospitalization of homeless persons with tuberculosis in the US